ViviGen® Cellular Bone Matrix outperforms MSC-based allografts and is equivalent to gold standard autograft
Share this article VIRGINIA BEACH, Va., Dec. 29, 2020 /PRNewswire/ -- ViviGen ® Cellular Bone Matrix — the first cellular allograft to recover and protect viable, lineage-committed bone cells — supports outcomes that are comparable to autograft and superior to a conventional mesenchymal stem cell (MSC)-based cellular allograft in even high-risk foot and ankle procedures, according to two recent peer-reviewed publications. Foot & Ankle Specialist showed that ViviGen supports fusion even in patients with comorbidities that create higher risk of nonunion, such as diabetes, thyroid diseas...
Source: prnewswire.com